SLG
BSTC

Stanley-Laman Group’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Stanley-Laman Group’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,190
Closed -$288K – 299
2017
Q3 		$288K Sell
6,190
-6,356
-51% -$304K 0.08% 190
2017
Q2 		$621K Sell
12,546
-2,343
-16% -$123K 0.17% 127
2017
Q1 		$816K Buy
14,889
+9,042
+155% +$479K 0.22% 112
2016
Q4 		$326K Buy
+5,847
New +$281K 0.1% 209

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Stanley-Laman Group's BSTC Position: Q4 2017 in Review

Stanley-Laman Group sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2017, closing a stake of 6,190 shares — an estimated $288K sold.

Stanley-Laman Group first reported a position in BSTC in Q4 2016 and held it in 4 quarters. The position peaked at $816K in Q1 2017. 88 funds tracked by Wall St. Rank hold BSTC as of Q4 2017.

  • Stanley-Laman Group reported no remaining BioSpecifics Technologies Corp. position as of Q4 2017 after selling out during the quarter.
  • Stanley-Laman Group sold 6,190 BioSpecifics Technologies Corp. shares in Q4 2017, an estimated $288K.
  • Stanley-Laman Group first reported a position in BioSpecifics Technologies Corp. in Q4 2016 and held it in 4 quarters.
  • Stanley-Laman Group's BioSpecifics Technologies Corp. position peaked at $816K in Q1 2017.
  • 88 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2017.

Based on Stanley-Laman Group's 13F filing for Q4 2017, filed 9 Feb 2018.